Targeted agents in epithelial ovarian cancer: review on emerging therapies and future developments.

Ecancermedicalscience · 2016 · PMC4817523 · PMID 27110282

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Addition of bevacizumab showed a trend towards improved PFS for the angiogenic gene upregulated subgroup [ 29 ].

also in 53,322 other papers

a strong trendno p-value reported

There was also a strong trend towards overall survival advantage, although this was not statistically significant (34.9 months versus 31.9 months) ( p < 0.208).

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.